Clinical Trial: A Phase 1/2 Study of Personalized PSMA Radiopharmaceutical Therapy
Study Status: NOT_YET_RECRUITING
Recruit Status: NOT_YET_RECRUITING
Condition: Cancer
Study Type: INTERVENTIONAL
Official Title: PROstate-specific Membrane Antigen DosImetry-Guided endoradiotherapY: A Phase 1/2 Study of Personalized PSMA Radiopharmaceutical Therapy (PRODIGY-1)
Brief Summary:
The goal of this clinical trial is to study a personalized regime of lutetium-177 (177Lu) prostate-specific membrane antigen (PSMA) radiopharmaceutical therapy (RPT) in patients with progressive and/or symptomatic, inoperable PSMA-expressing cancers of prostatic or other origins.The main questions it aims to answer are:To establish a dosimetry-based, personalized regime of 177Lu-PSMATo report on the efficacy of personalized 177Lu-PSMAParticipants (stratified by risk factors of toxicity) will receive up to 6…
Read more